Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts.

Only one of the PDXs (PDX377) showed a tendency to respond to the inhibition of IL-6 signaling (Figure 3A ), although the difference did not reach statistical significance.

also in 111,027 other papers